Serum ACE as a prognostic biomarker in COVID-19: A Case series
Kolberg, Espen Skarstein; Tonby, Kristian; Wickstrøm, Kristin; Riise, Anne Margarita Dyrhol; Holten, Aleksander Rygh; Amundsen, Erik Koldberg
Peer reviewed, Journal article
Accepted version
Åpne
Permanent lenke
https://hdl.handle.net/11250/2721321Utgivelsesdato
2020Metadata
Vis full innførselSamlinger
Originalversjon
10.1111/apm.13108Sammendrag
We have earlier proposed that serum ACE (s‐ACE) could be used as a biomarker for severity in COVID‐19 due to an assumed inverse relationship between ACE and ACE2. High s‐ACE could indicate lower ACE2 activity and therefore more widespread and severe SARS‐CoV2 infection, owing to virally mediated downregulation of ACE2 (1). Dysregulation of the Renin‐Angiotensin‐Aldosterone system (RAAS) are found in comorbidities known as risk factors for increased morbidity and mortality, such as hypertension and cardiovascular disease (2).